Bausch Health Companies BHC Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Business | ||||||
| Bausch + Lomb | $1.24B+9.4% | $1.41B+9.8% | $1.28B+7.1% | $1.28B+5.1% | $1.14B+3.5% | |
| Diversified | $185M-9.8% | $255M+11.8% | $258M-4.1% | $219M-12.7% | $205M+1.5% | |
| International | $285M+8.8% | $306M+9.7% | $286M-1.7% | $278M+0.7% | $262M-1.1% | |
| Salix | $639M+17.9% | $693M+9.3% | $716M+11.5% | $627M+12.4% | $542M+8.6% | |
| Solta Medical | $171M+51.3% | $137M-0.7% | $140M+25.0% | $128M+25.5% | $113M+28.4% | |
| Operating Income (Loss) by Business | ||||||
| Bausch + Lomb | $277M+53.9% | $396M+28.2% | $301M+6.4% | $248M-9.5% | $180M-25.6% | |
| Diversified | $112M-11.8% | $179M+14.0% | $182M-3.7% | $139M-16.3% | $127M+11.4% | |
| International | $88M+3.5% | $81M-17.3% | $90M-14.3% | $78M-9.3% | $85M-2.3% | |
| Salix | $468M+26.1% | $529M+15.0% | $570M+30.7% | $455M+20.7% | $371M+12.8% | |
| Solta Medical | $75M+41.5% | $55M-24.7% | $70M+32.1% | $54M+14.9% | $53M+32.5% | |
| SG&A by Business | ||||||
| Bausch + Lomb | $439M-1.8% | $436M0.0% | $429M+2.1% | $470M+9.6% | $447M+10.4% | |
| Diversified | $43M-4.4% | $40M+14.3% | $41M+2.5% | $43M-6.5% | $45M-6.3% | |
| International | $63M+21.2% | $64M+28.0% | $57M+5.6% | $63M+10.5% | $52M-1.9% | |
| Salix | $105M-5.4% | $100M-6.5% | $79M-46.3% | $112M+9.8% | $111M+8.8% | |
| Solta Medical | $35M+25.0% | $40M+21.2% | $31M+19.2% | $32M+23.1% | $28M+12.0% | |
| R&D by Business | ||||||
| Bausch + Lomb | $45M+60.7% | $40M+17.6% | $41M+41.4% | $35M+16.7% | $28M0.0% | |
| Diversified | $3M0.0% | $4M0.0% | $3M0.0% | $4M0.0% | $3M-25.0% | |
| International | $6M0.0% | $8M+14.3% | $7M+40.0% | $6M-14.3% | $6M+20.0% | |
| Salix | $19M+11.8% | $20M-13.0% | $21M+10.5% | $21M-30.0% | $17M-37.0% | |
| Solta Medical | $8M+60.0% | $6M0.0% | $9M+80.0% | $6M+100% | $5M+25.0% | |
| Additions by Business | ||||||
| Bausch + Lomb | $0-100% | $24.25M-10.2% | $24.25M— | $24.25M— | $24.25M— | |
| Diversified | $0— | $0— | $0— | $0— | $0— | |
| International | $0— | $0— | $0— | $0— | $0— | |
| Salix | $0— | $0— | $0— | $0— | $0— | |
| Solta Medical | $0-100% | $5.5M— | $5.5M— | $5.5M— | $5.5M— | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | ||||||
| Bausch + Lomb | $21M+148% | -$4M-105% | $0+100% | -$100M-1,211% | -$44M-257% | |
| Diversified | $0-100% | —— | —— | $18M+1,000% | $15M+267% | |
| International | $17M+146% | -$10M-119% | $0— | -$63M-342% | -$37M-1,025% | |
| Salix | $0— | $0— | $0— | $0— | $0— | |
| Solta Medical | $0— | $0— | $0— | $0— | $0— | |
| Goodwill by Business | ||||||
| Bausch + Lomb | $5.48B+3.2% | $5.5B+4.5% | $5.4B+1.4% | $5.41B+2.4% | $5.31B+0.4% | |
| Diversified | $1.58B-9.3% | $1.58B-10.1% | $1.73B-0.3% | $1.73B-1.0% | $1.74B+0.1% | |
| International | $880M+6.2% | $897M+13.3% | $891M+5.3% | $892M+7.2% | $829M-3.4% | |
| Salix | $1.73B-45.1% | $3.16B0.0% | $3.16B0.0% | $3.16B0.0% | $3.16B0.0% | |
| Solta Medical | $137M+19.1% | $137M+19.1% | $115M0.0% | $115M0.0% | $115M0.0% | |
| Goodwill, impairment loss by Business | ||||||
| Bausch + Lomb | $0— | $0— | $0— | $0— | $0— | |
| Diversified | $0-100% | $36.25M— | $36.25M— | $36.25M— | $36.25M— | |
| International | $0— | $0— | $0— | $0— | $0— | |
| Salix | $1.43B— | $0— | $0— | $0— | $0— | |
| Solta Medical | $0— | $0— | $0— | $0— | $0— | |
| Revenue by Product | ||||||
| Other revenues | $24M-25.0% | $28M-9.7% | $24M-14.3% | $26M+8.3% | $32M+33.3% | |
| Price Appreciation Credit | $2M0.0% | $15M-16.7% | $1M— | $0— | $2M— | |
| Product sales | $2.5B+12.3% | $2.77B+9.5% | $2.66B+7.1% | $2.5B+5.3% | $2.23B+4.6% | |
| Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues by Product | ||||||
| Other revenues | $17M-5.6% | $15M-6.3% | $15M+7.1% | $16M+45.5% | $18M+50.0% | |
| Product sales | $721M+5.6% | $783M+10.1% | $735M+7.8% | $748M+5.6% | $683M+8.8% | |
| Number of lawsuits pending by Geography | ||||||
| CA-BC | $10.0% | —— | $1— | $1— | $1— | |
| CA-QC | $10.0% | —— | $1— | $1— | $1— | |
| CANADA | $20.0% | —— | $2— | $2— | $2— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bausch Health Companies break its business down?
- Bausch Health Companies (BHC) reports revenue by business across 5 parts — Bausch + Lomb, Diversified, International, Salix and Solta Medical. Each is extracted from the segment footnotes and tracked over time.
- Where does Bausch Health Companies's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bausch Health Companies's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.